A study to determine antibody responses to HZ vaccine in selected rheumatic diseases treated with JAK-inhibitors (JAKi) pre- and post-Shingrix vaccination (weeks 4–6) and to identify factors associated with reduced immunogenicity
Latest Information Update: 11 Jul 2023
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Pharmacodynamics
Most Recent Events
- 11 Jul 2023 New trial record
- 03 Jun 2023 Preliminary results (n=32) presented at the 24th Annual Congress of the European League Against Rheumatism